The recent FDA user fee law for device makers includes provisions to help incorporate wider stakeholder input in agency decision-making, which should help reinforce CDRH’s recent efforts to gather more substantive views from patients on the risk-benefit trade-offs of medical devices, an agency official said recently.
“We don’t want to just listen to patients and have a non-quantitative way of making sure we incorporate their views,” said Michelle McMurry-Heath, CDRH associate director for science, at a...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?